GRIN Therapeutics Marks Milestone with First Patient Dosed in Groundbreaking Beeline Trial GRIN Therapeutics has initiated its global Phase 3 Beeline Trial, marking a historic moment for GRIN-NDD treatment advancements with the first patient dosed.

GRIN Therapeutics Marks Milestone with First Patient Dosed in Groundbreaking Beeline Trial #United_States #New_York #GRIN_Therapeutics #Radiprodil #Neurodevelopmental

GRIN Therapeutics Unveils Breakthrough Clinical Trial Insights for Radiprodil at AES Annual Meeting GRIN Therapeutics is set to present innovative methodologies for assessing the Beeline clinical trial of radiprodil, focusing on GRIN-related disorders at the American Epilepsy Society Annual Meeting.

GRIN Therapeutics Unveils Breakthrough Clinical Trial Insights for Radiprodil at AES Annual Meeting #United_States #Atlanta #GRIN_Therapeutics #Radiprodil #Neurodevelopmental_Disorders

GRIN Therapeutics Unveils Significant Updates for Radiprodil at 2025 International Epilepsy Congress GRIN Therapeutics showcased crucial clinical developments for Radiprodil aimed at treating GRIN-related neurodevelopmental disorders at the 2025 ILAE Congress.

GRIN Therapeutics Unveils Significant Updates for Radiprodil at 2025 International Epilepsy Congress #USA #New_York #GRIN_Therapeutics #Radiprodil #Neurodevelopmental_Disorders

GRIN Therapeutics Partners with Angelini Pharma to Advance Radiprodil Development Globally GRIN Therapeutics has partnered with Angelini Pharma to develop radiprodil for global markets. This strategic collaboration enhances research on neurodevelopmental disorders and involves significant investments.

GRIN Therapeutics Partners with Angelini Pharma to Advance Radiprodil Development Globally #USA #New_York #GRIN_Therapeutics #Radiprodil #Angelini_Pharma

GRIN Therapeutics and Angelini Pharma Unite to Advance Radiprodil for Global Development GRIN Therapeutics partners with Angelini Pharma to develop Radiprodil beyond North America, securing $140M in financing to enhance treatment for neurological disorders.

GRIN Therapeutics and Angelini Pharma Unite to Advance Radiprodil for Global Development #USA #New_York #GRIN_Therapeutics #Radiprodil #Angelini_Pharma

GRIN Therapeutics Achieves Positive Orphan Designation for Radiprodil in the EU for GRIN-NDD GRIN Therapeutics secures a favorable opinion for Radiprodil's orphan designation in the EU, aiming to treat GRIN-NDD, highlighting progress in rare disease therapies.

GRIN Therapeutics Achieves Positive Orphan Designation for Radiprodil in the EU for GRIN-NDD #USA #New_York #GRIN_Therapeutics #Radiprodil #GRIN-NDD

GRIN Therapeutics Secures FDA Orphan Drug Status for Innovative Radiprodil Treatment GRIN Therapeutics has received Orphan Drug designation from the FDA for Radiprodil, aimed at treating GRIN-related neurodevelopmental disorders, highlighting advancements in pediatric care.

GRIN Therapeutics Secures FDA Orphan Drug Status for Innovative Radiprodil Treatment #USA #New_York #GRIN_Therapeutics #Radiprodil #Orphan_Drug

GRIN Therapeutics Shares Promising Data From Radiprodil Honeycomb Trial at AES Meeting GRIN Therapeutics presented significant data from its Honeycomb trial at the AES Annual Meeting, highlighting radiprodil's efficacy for GRIN-related disorders.

GRIN Therapeutics Shares Promising Data From Radiprodil Honeycomb Trial at AES Meeting #United_States #Los_Angeles #GRIN_Therapeutics #Radiprodil #Neurodevelopmental